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COMPLEMENT DEPOSITION 
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Cutaneous Immunopathology Unit and the Departments of Dermatology and Immunology, Mayo Clinic and Mayo 
Foundation, Rochester, M innesota, and the Diagnostic Clinic of Houston (SFB) Houston, Texas, U.S. A . 
Im munopathologic investigations were conducted on t he sera and oral mucosal tissue 
specimens of 23 patients with cicatricial pemphigoid. A linear, continuous basement 
membrane zone pattern was noted in 83% of oral mucosal biopsy specimens studied. This 
pattern is indistinguishable from the pattern noted in immunofluorescence studies of bullous 
pemphigoid, herpes gestationis, and some cases of desquamative gingivitis. Complement 
studies provided data supportive of classical pathway activation in cicatricial pemphigoid 
tissue. Deposition oflgA with Factor B, properdin, and C3 raised the possibility of alternative 
pathway activation, a question requiring further study. Circulating antibasement membrane 
zone antibodies were noted in the sera of two patients with cicatr icial pemphigoid. 
Cicatricial (benjgn mucous membrane) pem-
phigoid (CP) is a well-defined disease character-
ized by its chronic course, its scarring nature, and 
its predilection for the mucosal surfaces. Civatte 
[1) and Lever [2] separated CP from pemphigus 
vulgaris by the presence of subepithelial bullae in 
CP. Lever !3 ], Hardy et al [4), and Shklar and 
McCarthy !51 reported large series defining the 
distinct clinical nature of the disease. Lortat-Jacob 
[6] described a disease. dermatite bulleuse muco-
synechante et atrophiante, which is indistinguish-
able from CP (7]. The clinical and histopathologic 
characteristics of CP suggest an etiologic relation-
ship between CP and bullous pemphigoid (BP). 
Several recent investigations [7- 14] have dem-
onstrated the presence of tissue-bound immuno-
globulin and complement components C3 and C4 
at the basement membrane zone (BMZ) in CP. 
The linear pattern of this BMZ staining is identical 
to the immunofluorescent (IF) pattern of BP. The 
identical direct IF findings lend credence to an 
etiologic relationship between CP and BP. Further 
support for this relationship is the presence of 
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circulating anti-BMZ antibodies in the sera of 
several patients with cicatricial pemphigoid 
[15-18]. 
We have investigated sera and tissue samples 
from 23 patients with CP by IF techniques. Two of 
21 patients' sera demonstrated cir culating anti-
BMZ antibodies. Nineteen of 23 patients' tissues 
demonstrated linear BMZ deposition of immuno-
globulins as well as components of both the classi-
cal and alternative complement pathways and 
fibrin. 
PATIE:-.:T~ A:\0 :\1ETHOD, 
Twenty-three patients with CP were studied. Four of 
these patients. whose clinical. histopathologic, and im-
munopathologic findings have been reported elsewhere 
[19 ], had their disea e begin as desquamative gingivitis 
which then e\•olved into CP. 
Almo t all immunopathologic tests had been con-
ducted since the inception of our Cutaneous Immunopa-
thology Unit in June 1973. erum and tissue samples 
were obtamed by standard procedures and were tested 
immediateh· or were stored at - I0°C until tested. Oral 
mucosal specimens were obtained in all 23 patients, skin 
specimens in 2 patients. and vaginal mucosal specimens 
in l patient. Twenty of 23 of the oral mucosal histopatho-
logic specimens revealed subepithelial bullae. In 3 
patients, the histopathologic specimens were nonspecific. 
Controls consisted of sera and tissues from other patients 
with oral mucosal inflammatory diseases. the results of 
which have been reported elsewhere [20 ). 
Antihuman lgG was prepared in goats, assayed. and 
conjugated with fluorescein i8othiocyanate by methods 
pre\·iously reiewed in detail [21]. Labeled antisera to 
lgM. * lgA. * C3," and fibrin.* as well as unlabeled 
antisera to C4t and labeled goat antirabbit • and rabbit 
antigoat IgG, * were purchased. 
• Hyland Division , Travenol Laboratories. Inc .. Costa 
Mesa, Calif. 92626. 
t Behring Diagnostics, American Hoechst Phar-
maceuticals, Sommerville, N. J. 08876. 
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Rabbit antisera t.o Clq and to properdin Factor B were 
prepared and tested by the methods of Morse and 
Christian [22] and Gotze and Miiller-Eberhard [23), 
respectively. Goat antiserum to properdin was made after 
isolating human properdin by the method of Pensky et al 
[24]. Details of the preparation and use of these antisera 
(to Clq. Factor B. and properdin) have been published 
previously in detail [25-27 ]. 
All antisera were checked for specificity by both double 
immunodiffussion (Ouchterlony) and immunoelectro-
phoresis. Units of antisera, fluorescein-protein ratios, 
antibody protein assays, and dilutions at which the 
conjugated antisera were used conformed to previously 
determined standards [21). 
Serum specimens were tested for circulating anti-
bodies by t he indirect IF staining technique according to 
establ ished procedures [21) using monkey esophageal 
mucosal sections. Tissue specimens were tested for fixed 
immunoglobulins and complement components by both 
the di.rect and the modified indirect IF procedures as 
previously reported in detail [21-29]. 
Direct IF testing of C'P tissue specimens was conducted 
with antisera to lgG, IgA, lgM, fibrin, and C3 by 
previously described methods [21- 27). The modified 
indirect IF staining method [25-29] was used to test for 
the presence of Clq. C4. Factor B, and properdin. Briefly, 
this method involves t reating tissue specimens first with 
rabbit anti-Clq, rabbit anti-C4. or rabbit anti-Factor B 
and then with labeled goat antirabbit lgG. In a similar 
fashion goat antiproperdin was used first, followed by 
labeled rabbit antigoat lgG. The specificity controls for 
the modified indirect IF technique have been reported 
[25-27]. 
RESL;LTS 
The Table is a summary of our immunopatho-
logic observations of the oral mucosal lesions of 23 
patients with CP. Both cutaneous lesions and the 
vaginal mucosal lesion also demonstrated a linear 
BMZ pattern by direct IF testing with deposition 
of immunoglobulins and complement components. 
A continuous, linear BMZ pattern was found in 
19 of 23 or 83% of the oral mucosal biopsy 
specimens by the direct IF test. All 19 tissue 
specimens had the deposition of one or more 
TABLE. Summary of immunopathologic obseruations of 
cicatricial pemphigoid mucosal lesions 
Linear BMZ panern 
J\nti~era 
:--lumber Percent positive 
lgG 9/ 23 39 
lgA 8/20 40 
lgM 6/21 29 
C3 17/21 81 
C!q• 7/11 64 
C4• 2/4 50 
Factor B• 5/10 50 
Properdin" 7/11 64 
Fibrin 15/23 65 
P ositive BMZ pattern 19/23 83 
• Modified indirect fF staining employed 
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F1c. l. Linear. continuous deposition of lgA at the 
basement membrane zone of an oral mucosal biopsy 
specimen. This pattern is typica l of the pemphigoid 
spectrum of disease ( x 250). 
complement components at the BMZ. Thirteen of 
the 19 positive tissue specimens had the deposition 
of 1 or more immunoglobulin at the BMZ. Interest-
ingly, lgG deposition was noted in ouly 9 of 23 
tissues tested. lgA deposition (Fig. 1) occurred in 8 
of 20 and IgM in 6 of 21 tissues tested, respectively. 
Six had deposition of 2 or more complement 
components and fibrin at the BMZ. 
A continuous. linear BMZ pattern similar to the 
one that we report herein has been seen only in oral 
mucosal specimens from patients with desquama-
tive gingivitis [19] and BP. Only 2 results (C3 and 
fibrin in a linear BMZ pattern) in 42 patients with 
miscellaneous oral mucosal diseases have been 
noted that could be questionably interpreted as 
positive linear BMZ staining [20]. 
Evidence for activation of the classical comple-
ment pathway in lesions of CP can be gleaned from 
the deposition of Clq, one of the subunits of the 
first component of complement, and C4, another 
early reacting component of the classical sequence 
These components were noted in 7 of 11 and 2 of 4 
specimens. respectively. 
lgA deposition (Fig. 1) in 8 of 20 t issue speci-
mens studied is noteworthy as this immunoglobulin 
does not characteristically activate the classical 
complement pathway but can activate the alter-
native pathway [23]. Alternative pathway compo-
Jan. 1977 
nents, Factor B and properdin, were present in 
a high percentage of lesions studied. in 5 of 10 
and 7 of 11 specimens, respectively. In 4 pa-
tients' tissues, lgA, C3, Factor B, and proper-
din deposition were apparent at the BMZ in 
serial sections. As in pemphigus [25] and BP [26}. 
specific absorption of anti-Factor B with Factor B 
and antiproperdin with properdin resulted in 
blocking of the IF staining. 
Circulating anti-BMZ antibodies were present in 
2 of 23 patients with CP. In both patients t he 
antibodies were present for a short period of time (1 
month and 4 months) , after which the antibodies 
were absent on repeated testing. The titers were 
1:320 and 1:80. The substrate for indirect IF testing 
at the time of the positive tests was guinea-pig 
esophagus. Both of these patients represent some-
what atypical cases of CP and will be reported 
elsewhere. No positive indirect IF tests have been 
noted since June 1973, when monkey esophageal 
mucosa became our standard substrate. 
01. CUSSIO~ 
Our findings are consistent with the reports of 
others [7- 13 ] who have noted deposition of immu-
noglobulins C3 and C4 at the BMZ of CP lesions. 
Nineteen of 23 (83%) of the oral mucosal biopsy 
specimens studied were positive. Thirteen of the 19 
specimens had the deposition of 1 or more immu-
noglobulin with or without 1 or more complement 
components at the BMZ in a continuous, linear 
pat tern. The presence of 2 or more complement 
components in the oral mucosal specimens, even in 
the absence of immunoglobulin deposition, in-
creased the number of positive results from 13 of 23 
to 19 of 23 patients . 
A few of our patients had negative results on the 
first oral mucosal biopsy specimen. onl~, to have a 
positive result when the study was repeated on 
" better" tissue. The mucosal surfaces of CP are 
prone to separation from the submucosa due to 
the nature of the subepithelial bullous process. 
With the loss of the mucosal-submucosal interface. 
specificity of immunopathologic interpretation is 
lost . Also, tissue which has been ulcerated or 
eroded is inadequate for interpretation. For these 
reasons, we have selected the areas of perilesional 
erythema as the site of our biopsy specimens. With 
" better" tissue selection positive results are much 
more frequent and add an important diagnostic 
method to t he study of CP. 
The IF pattern reported here (Figs. 1. 2) is a 
linear. continuous deposition of immunoreactive 
proteins at the BMZ. This pattern is distinctive for 
the pemphigoid spectrum of diseases which now 
appears to include CP, BP, herpes gestationis 
[27,28,30 j, and perhaps desquamative gingivitis 
[19]. 
The Jack of lgG deposition in the majority of 
tissues tested is somewhat puzzling, however, in 
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FIG. 2. Linear, continuous deposition of C3 at the 
basement membrane zone of an oral mucosal biopsy 
specimen (Y. 250). 
light of the other reports [8,10, 12). Only 9 of 23 CP 
biopsies tested by us demonstrated IgG deposition 
to the BMZ. The explanation for this finding is not 
clear at the present time, although similar findings 
have recently been noted in both BP (31] and 
herpes gestat ions [27]. Deposition of C3. a pivotal 
protein in the complement sequence which ap-
pears at the interface of both the classical and 
alternative pathways, appears to be a more sensi-
tive. specific immunopathologic finding in all of 
these diseases. 
Provost and Tomasi [28,29] and Jordon et al [261 
have reported deposition of Clq, C4, and C3, in 
addition to IgG and IgM at the BMZ of cutaneous 
lesions of BP by IF techniques. These studies 
provide immunopathologic evidence for activation 
of the classical pathway in CP. Immunoglobulins 
G and M characteristically acti,·ate the classical 
pathway and were present in 11 of 23 patients. 
Early classical pathway components. Clq and C4. 
were present in the majority of tissue specimens so 
tested, and C3 was present in 17 of 21 tissue speci-
mens. On the other hand, one cannot state un-
equivocally that the classical pathway is activated 
on the basis of immunopathologic observations 
alone. a lthough our data would support this con-
tention. 
The finding of lgA deposition in about one-half 
of CP tissue specimens tested is also worthy of 
note. Alt hough all immunoglobulins when aggre-
gated or altered may activate the alternative path-
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way,:): lgA may activate complement only by that 
pathway [23 ]. Factor B and properdin, two com-
ponents of the alternative pathway, were found 
bound to the BMZ in 5 of 10 and 7 of 11 specimens, 
respectively. In addition, 4 of our patients' tissues 
demonstrated IgA, C3, Factor B, and properdin at 
the BMZ in serial sections. Similar findings have 
been noted in a few patients with dermatitis her-
petiformis [32] where IgA deposition characteris-
tically occurs. 
Binding of Factor B and properdin in tissues, 
however, may not be indicative of true alternative 
pathway activation. Recently Schreiber et al [33] 
and Fearon and Austen {34] have demonstrated 
that Factor B and properdin can bind to C3b, thus 
stabilizing the ''C3b-dependent C3 convertase." 
Classical pathway activation of C3, which was 
apparent in all specimens with Factor B and 
properdin deposition (i.e., Clq and C4 deposition 
as well), produces C3b which presumably binds to 
the BMZ with other immunoreactive proteins. 
Thus, deposition of Factor B and properdin can be 
explained by their binding to C3b at the BMZ. 
Similar findings in BP [26,28,29] and. more re-
cently, in herpes gestationis [27,30] are also best 
explained by this phenomenon.· The question of 
true alternative pathway activation, independent 
of generation of the C3b-dependent C3 convertase, 
in all of these diseases requires further study. 
The presence of circulating anti-BMZ antibodies 
in the sera of 2 of these patients was a transient 
phenomenon lasting only 1 and 4 months until 
consistently negative results were obtained. The 
disease characteristics and substrate specificities 
have been discussed by other investigators [15- 18]. 
These two patients and a third with circulating 
anti-BMZ antibodies will be reported in a separate 
communication. 
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